Phase 2 Study

Summary

GEn-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis. Subjects will be given a second dose approximately 8 hours after the first dose and will continue with twice daily dosing (BID regimen) for 5 days.

Study Details

ID#: NCT05795465
‍Age: 18 - 80 years
Gender: All
Healthy Subjects: No

Study Phase: Phase 2
Recruitment Status: Recruiting

View more on www.clinicaltrials.gov

A Study of GEn-1124 in Subjects with Acute Respiratory Distress Syndrome (ARDS)

ClinicalTrials.gov ID NCT05795465

Phase 2 Clinical Study

Summary

Study Details